Volume 11, Issue 4 (Vol.11 No.4 Jan 2023)                   rbmb.net 2023, 11(4): 599-613 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Iswanti F C, Putri Q H, Prijanti A R, Djauzi S, Sadikin M, Witarto A B et al . The Use of Chitosan Nanoparticles for Delivery of CpG ODN in Treatment of Allergic Balb/C Mice. rbmb.net 2023; 11 (4) :599-613
URL: http://rbmb.net/article-1-917-en.html
Department of Biochemistry and Molecular Biology Faculty of Medicine, Universitas Indonesia, Indonesia.
Abstract:   (1601 Views)
Background: This study aims to prepare high stability chitosan nanoparticles (CNP) and examine the ability of CNP in CpG-ODN delivery when treating allergic mice model.
 
Methods: Preparation and characterization of CNP were performed by ionic gelation, dynamic light scattering, and zeta sizer. The CNP cytotoxicity and activation ability of CpG ODN delivered with CNP were tested using a cell counting kit-8 and Quanti blue method. Allergic mice were injected intraperitoneal with 10 ug ovalbumin on day 0 and 7, and then treated with intranasal CpG ODN/CpG ODN, delivered with CNP/CNP, on the third week three times per week for three weeks. The ELISA method measured cytokine and IgE profiles in the allergic mice’s plasma and spleen.
 
Results: CNP results have sizes 27.73 nm±3.67 dan 188.23 nm±53.47, spherical in shape and non-toxic, and did not alter the NF-κB activation of CpG ODN in RAW-blue cells. The application of CpG ODN delivered by chitosan nanoparticles shows no statistical difference between groups of IFN-γ, IL-10, and IL-13 in Balb/c mice’s plasma and spleen, in contrast with IgE level.

Conclusions: The results showed that using chitosan nanoparticles as a delivery system for CpG ODN has the potency to safely CpG ODN efficacy.
 
Full-Text [PDF 434 kb]   (1141 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2022/04/13 | Accepted: 2022/05/7 | Published: 2023/04/3

References
1. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:(1-15). [DOI:10.3389/fped.2019.00246] [PMID] [PMCID]
2. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3(1):1-11. [DOI:10.1186/s40733-016-0029-3] [PMID] [PMCID]
3. Immunology AAoAAa. Allergies Overview 2021. Available from: https://www.aaaai.org/Conditions-Treatments/Allergies.
4. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7(1):12. [DOI:10.1186/1939-4551-7-12] [PMID] [PMCID]
5. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461. [DOI:10.3389/fimmu.2014.00461] [PMID] [PMCID]
6. Nie L, Cai SY, Shao JZ, Chen J. Toll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals. Front Immunol. 2018;9:1523. [DOI:10.3389/fimmu.2018.01523] [PMID] [PMCID]
7. Javaid N, Yasmeen F, Choi S. Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods. Pharmaceutics. 2019;11(9):441. [DOI:10.3390/pharmaceutics11090441] [PMID] [PMCID]
8. Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. Pharmaceutics. 2017;9(4):53. [DOI:10.3390/pharmaceutics9040053] [PMID] [PMCID]
9. Elieh-Ali-Komi D, Hamblin MR. Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. Int J Adv Res (Indore). 2016;4(3):411-427.
10. Iswanti FC, Nurulita I, Djauzi S, Sadikin M, Witarto AB, Yamazaki T. Preparation, characterization, and evaluation of chitosan-based nanoparticles as CpG ODN carriers. Biotechnol Biotechnol Equip. 2019:33 (1); 390-396. [DOI:10.1080/13102818.2019.1578690]
11. Mardliyati E, El Muttaqien S, Setyawati DR. Synthesis of chitosan-TPP nanoparticles by ionic gelation method: effect of concentration and volume ratio on characteristics of particles. Proceedings of the Scientific and Technological Meeting; 2012:90-93.
12. Iswanti FC, Djauzi S, Sadikin M, Witarto AB, Yamazaki T. Comparison of Ovalbumin Sensitized Mice Model for Allergy: A Preliminary Study. eJournal Kedokteran Indonesia. 2018;6(3):183-9. [DOI:10.23886/ejki.6.9906.]
13. Li HT, Zhang TT, Chen ZG, Ye J, Liu H, Zou XL, et al. Intranasal administration of CpG oligodeoxynucleotides reduces lower airway inflammation in a murine model of combined allergic rhinitis and asthma syndrome. Int Immunopharmacol. 2015;28(1):390-8. [DOI:10.1016/j.intimp.2015.06.028] [PMID]
14. Anitha A, Sowmya S, Sudheesh Kumar PT, Deepthi S, Chennazi KP, et al. Chitin and chitosan in selected biomedical applications. Progress in Polymer Science. 2014;39:1644-67. [DOI:10.1016/j.progpolymsci.2014.02.008]
15. Wang W, Meng Q, Li Q, Liu J, Zhou M, Jin Z, Zhao K. Chitosan Derivatives and Their Application in Biomedicine. Int J Mol Sci. 2020;21(2):487. [DOI:10.3390/ijms21020487] [PMID] [PMCID]
16. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10:483-507. [DOI:10.2147/DDDT.S99651] [PMID] [PMCID]
17. Jonassen H, Kjøniksen AL, Hiorth M. Stability of chitosan nanoparticles cross-linked with tripolyphosphate. Biomacromolecules. 2012;13(11):3747-56. [DOI:10.1021/bm301207a] [PMID]
18. Koukaras EN, Papadimitriou SA, Bikiaris DN, Froudakis GE. Insight on the formation of chitosan nanoparticles through ionotropic gelation with tripolyphosphate. Mol Pharm. 2012;9(10):2856-62. [DOI:10.1021/mp300162j] [PMID]
19. Bugnicourt L, Ladavière C. Interests of chitosan nanoparticles ionically cross-linked with tripolyphosphate for biomedical applications. Progress in Polymer Science. 2016;60:1-17. [DOI:10.1016/j.progpolymsci.2016.06.002]
20. Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces. 2012;90:21-7. [DOI:10.1016/j.colsurfb.2011.09.042] [PMID]
21. DoĞAn M. Preparation of chitosan nanoparticles and characterization studies. Cumhuriyet Medical Journal. 2020;42(3):344-350. [DOI:10.7197/cmj.vi.795367]
22. Popova EV, Zorin IM, Domnina NS, Novikova II, Krasnobaeva IL. Chitosan-Tripolyphosphate Nanoparticles: Synthesis by the Ionic Gelation Method, Properties, and Biological Activity. Russ J Gen Chem. 2020;90:1304-11. [DOI:10.1134/S1070363220070178]
23. Bondar OV, Saifullina DV, Shakhmaeva II, Mavlyutova II, Abdullin TI. Monitoring of the Zeta Potential of Human Cells upon Reduction in Their Viability and Interaction with Polymers. Acta Naturae. 2012;4(1):78-81. [DOI:10.32607/20758251-2012-4-1-78-81] [PMID] [PMCID]
24. Gatoo MA, Naseem S, Arfat MY, Dar AM, Qasim K, Zubair S. Physicochemical properties of nanomaterials: implication in associated toxic manifestations. Biomed Res Int. 2014;2014:498420:1-8. [DOI:10.1155/2014/498420] [PMID] [PMCID]
25. Pocket guide for asthma management and prevention: Global Initiative of Asthma (GINA); 2021.
26. Brandt EB, Strait RT, Hershko D, Wang Q, Muntel EE, Scribner TA, et al. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest. 2003 Dec;112(11):1666-77. [DOI:10.1172/JCI19785] [PMID] [PMCID]
27. Aun MV, Bonamichi-Santos R, Arantes-Costa FM, Kalil J, Giavina-Bianchi P. Animal models of asthma: utility and limitations. J Asthma Allergy. 2017;10:293-301. [DOI:10.2147/JAA.S121092] [PMID] [PMCID]
28. Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. Sci Immunol. 2019;4(33):eaau6085. [DOI:10.1126/sciimmunol.aau6085] [PMID] [PMCID]
29. Hanagata N. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Int J Nanomedicine. 2017;12:515-531. [DOI:10.2147/IJN.S114477] [PMID] [PMCID]
30. Kim DH, Sohn JH, Park HJ, Lee JH, Park JW, Choi JM. CpG Oligodeoxynucleotide Inhibits Cockroach-Induced Asthma via Induction of IFN-γ⁺ Th1 Cells or Foxp3⁺ Regulatory T Cells in the Lung. Allergy Asthma Immunol Res. 2016;8(3):264-75. [DOI:10.4168/aair.2016.8.3.264] [PMID] [PMCID]
31. Meng W, Yamazaki T, Nishida Y, Hanagata N. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC biotechnol. 2011;11(88):1-9. [DOI:10.1186/1472-6750-11-88] [PMID] [PMCID]
32. Alspach E, Lussier DM, Schreiber RD. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harb Perspect Biol. 2019;11(3):a028480. [DOI:10.1101/cshperspect.a028480] [PMID] [PMCID]
33. Peng Z, Wang H, Mao X, HayGlass KT, Simons FE. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. Int Immunol. 2001 Jan;13(1):3-11. [DOI:10.1093/intimm/13.1.3] [PMID]
34. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine. 2012;7:2181-95. [DOI:10.2147/IJN.S30197] [PMID] [PMCID]
35. Wu N, Wen ZS, Xiang XW, Huang YN, Gao Y, Qu YL. Immunostimulative Activity of Low Molecular Weight Chitosans in RAW264.7 Macrophages. Mar Drugs. 2015;13(10):6210-25. [DOI:10.3390/md13106210] [PMID] [PMCID]
36. Corthay A. How do regulatory T cells work? Scand J Immunol. 2009;70(4):326-36. [DOI:10.1111/j.1365-3083.2009.02308.x] [PMID] [PMCID]
37. Givens BE, Geary SM, Salem AK. Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma. Immunotherapy. 2018;10(7):595-604. [DOI:10.2217/imt-2017-0142] [PMID] [PMCID]
38. Lacy P. Eosinophil Cytokines in Allergy. Cytokine Effector Functions in Tissues. Academic Press. 2017:173-218. [DOI:10.1016/B978-0-12-804214-4.00011-7]
39. Li Y, Liu H, Xu QS, Du YG, Xu J. Chitosan oligosaccharides block LPS-induced O-GlcNAcylation of NF-κB and endothelial inflammatory response. Carbohydr Polym. 2014;99:568-78. [DOI:10.1016/j.carbpol.2013.08.082] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb